These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 25398516)

  • 1. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
    Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
    Gurka MK; Chen LN; Bhagat A; Moures R; Kim JS; Yung T; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2015 Feb; 10():44. PubMed ID: 25890265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proctitis following stereotactic body radiation therapy for prostate cancer.
    Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
    Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients.
    D'Agostino G; Franzese C; De Rose F; Franceschini D; Comito T; Villa E; Alongi F; Liardo R; Tomatis S; Navarria P; Mancosu P; Reggiori G; Cozzi L; Scorsetti M
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e173-e178. PubMed ID: 27389021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
    Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
    Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15).
    Aghdam N; Pepin A; Buchberger D; Hirshberg J; Lei S; Ayoob M; Danner M; Yung T; Kumar D; Collins BT; Lynch J; Kataria S; Suy S; Collins SP
    Front Oncol; 2020; 10():1060. PubMed ID: 32719744
    [No Abstract]   [Full Text] [Related]  

  • 12. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.
    Katz AJ; Santoro M; Diblasio F; Ashley R
    Radiat Oncol; 2013 May; 8():118. PubMed ID: 23668632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience.
    Koskela K; Palmgren JE; Heikkilä J; Virsunen H; Sailas L; Auvinen P; Seppälä J; Kataja V
    Acta Oncol; 2017 Jul; 56(7):978-983. PubMed ID: 28514930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency preservation following stereotactic body radiation therapy for prostate cancer.
    Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
    Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
    Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
    Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
    Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
    J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
    Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
    Front Oncol; 2020; 10():555. PubMed ID: 32432033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 37.